ES2965009T3 - Terapia combinada contra el cancer - Google Patents

Terapia combinada contra el cancer Download PDF

Info

Publication number
ES2965009T3
ES2965009T3 ES17709038T ES17709038T ES2965009T3 ES 2965009 T3 ES2965009 T3 ES 2965009T3 ES 17709038 T ES17709038 T ES 17709038T ES 17709038 T ES17709038 T ES 17709038T ES 2965009 T3 ES2965009 T3 ES 2965009T3
Authority
ES
Spain
Prior art keywords
cells
peptide
ido
patients
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17709038T
Other languages
English (en)
Spanish (es)
Inventor
Mads Andersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Biotech ApS
Original Assignee
IO Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1603805.1A external-priority patent/GB201603805D0/en
Priority claimed from GBGB1610018.2A external-priority patent/GB201610018D0/en
Application filed by IO Biotech ApS filed Critical IO Biotech ApS
Application granted granted Critical
Publication of ES2965009T3 publication Critical patent/ES2965009T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES17709038T 2016-03-04 2017-03-03 Terapia combinada contra el cancer Active ES2965009T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1603805.1A GB201603805D0 (en) 2016-03-04 2016-03-04 Combination
GBGB1610018.2A GB201610018D0 (en) 2016-06-08 2016-06-08 Combination
PCT/EP2017/055093 WO2017149150A1 (en) 2016-03-04 2017-03-03 Combination therapy against cancer

Publications (1)

Publication Number Publication Date
ES2965009T3 true ES2965009T3 (es) 2024-04-10

Family

ID=58231605

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17709038T Active ES2965009T3 (es) 2016-03-04 2017-03-03 Terapia combinada contra el cancer

Country Status (13)

Country Link
US (2) US20190343940A1 (enExample)
EP (2) EP3423087B1 (enExample)
JP (3) JP2019507180A (enExample)
DK (1) DK3423087T3 (enExample)
ES (1) ES2965009T3 (enExample)
FI (1) FI3423087T3 (enExample)
HR (1) HRP20240052T1 (enExample)
HU (1) HUE064857T2 (enExample)
LT (1) LT3423087T (enExample)
PL (1) PL3423087T3 (enExample)
PT (1) PT3423087T (enExample)
SI (1) SI3423087T1 (enExample)
WO (1) WO2017149150A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
HUE064857T2 (hu) * 2016-03-04 2024-04-28 Io Biotech Aps Kombinációs terápia a rák ellen
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
CN110546509A (zh) 2017-04-28 2019-12-06 戊瑞治疗有限公司 用cd80细胞外结构域多肽进行治疗的方法
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
WO2019102265A1 (en) * 2017-11-23 2019-05-31 Theraphage Inc. Peptide displaying bacteriophage nanoparticles and related compositions and methods
EP3713645A1 (en) * 2017-11-24 2020-09-30 IO Biotech APS Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc)
WO2019165077A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
AU2019361923B2 (en) 2018-10-15 2026-07-09 Five Prime Therapeutics, Inc. Combination therapy for cancer
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
AU2020224137B2 (en) 2019-02-22 2026-01-08 Five Prime Therapeutics, Inc. CD80 extracellular domain-Fc fusion proteins for treating PD-L1 negative tumors
MX2021013272A (es) 2019-05-03 2021-11-17 Five Prime Therapeutics Inc Formulaciones farmaceuticas que contienen proteinas de fusion fc de dominio extracelular de cd80.
KR102653960B1 (ko) * 2020-07-23 2024-04-03 의료법인 성광의료재단 암 치료를 위한 면역체크포인트 억제제의 병용 요법
BR112023017582A2 (pt) 2021-03-05 2023-12-05 Univ Basel Composições para o tratamento de doenças ou condições associadas ao ebv
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
GB202103673D0 (en) * 2021-03-17 2021-04-28 Io Biotech Aps Combination therapy for cancer
CN117642432A (zh) * 2021-05-17 2024-03-01 威斯康星校友研究基金会 用于诱导免疫耐受的合成蛋白
EP4479085A1 (en) * 2022-02-18 2024-12-25 ModernaTX, Inc. Mrnas encoding checkpoint cancer vaccines and uses thereof
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy
WO2026008017A1 (en) * 2024-07-03 2026-01-08 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US20100055111A1 (en) * 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
DK2280721T3 (da) * 2008-04-17 2018-01-29 Io Biotech Aps Indoleamin-2, 3-dioxygenasebaseret immunterapi
ES2918580T3 (es) * 2011-10-17 2022-07-19 Io Biotech Aps Inmunoterapia basada en PD-L1
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
PH12020550847A1 (en) * 2014-02-04 2022-05-11 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
ES2715018T3 (es) * 2014-05-30 2019-05-31 Ventana Med Syst Inc Ensayo múltiple para puntuar mejor los tejidos tumorales teñidos para PD-L1
HUE064857T2 (hu) * 2016-03-04 2024-04-28 Io Biotech Aps Kombinációs terápia a rák ellen

Also Published As

Publication number Publication date
LT3423087T (lt) 2024-01-25
US20190343940A1 (en) 2019-11-14
EP3423087A1 (en) 2019-01-09
PT3423087T (pt) 2023-12-28
HRP20240052T1 (hr) 2024-03-29
PL3423087T3 (pl) 2024-05-20
FI3423087T3 (fi) 2023-12-15
WO2017149150A1 (en) 2017-09-08
JP2024045180A (ja) 2024-04-02
JP7417645B2 (ja) 2024-01-18
EP3423087B1 (en) 2023-11-15
HUE064857T2 (hu) 2024-04-28
EP4316517A2 (en) 2024-02-07
JP2019507180A (ja) 2019-03-14
US20220257741A1 (en) 2022-08-18
DK3423087T3 (da) 2023-12-18
SI3423087T1 (sl) 2024-03-29
EP4316517A3 (en) 2024-05-29
JP7785817B2 (ja) 2025-12-15
JP2022068348A (ja) 2022-05-09

Similar Documents

Publication Publication Date Title
JP7417645B2 (ja) がんに対する組合せ療法
Keenan et al. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice
Vacchelli et al. Trial watch: Peptide vaccines in cancer therapy
ES2926386T3 (es) Composición para el tratamiento del cáncer
Clark et al. Current status of therapeutic HPV vaccines
JP5955771B2 (ja) 細胞ベースの抗癌組成物ならびに当該物の製造方法および使用方法
ES2965957T3 (es) Una vacuna junto con un inhibidor del punto de control inmunitario para usar en el tratamiento del cáncer
JP2019515900A (ja) がんを処置するためのＴｏｌｌ様レセプター９アゴニストおよび腫瘍抗原を含む粒子の腫瘍内送達
US11351237B2 (en) CMV-based intra-tumoral cancer therapies
EP3265120B1 (en) Method
Pellom et al. Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009
KR20250044945A (ko) 기존의 미생물 면역을 활용한 암 치료
Sun et al. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes
CN105435218A (zh) 预防乳腺癌复发的疫苗
MX2007008013A (es) Metodos para producir, mejorar y sostener respuestas inmunes contra epitopos i-restringidos clase mhc por propositos profilacticos o terapeuticos.
Zhao et al. A co-formulated vaccine of irradiated cancer cells and cowpea mosaic virus improves ovarian cancer rejection
Masuko et al. Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy
KR20140131925A (ko) 자가 암 세포 백신
Barr et al. Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer
KR20080042097A (ko) 수포에 담긴 불완전 리보솜 생성물（ＤＲｒｉｂｂｌｅ） 및면역 반응을 자극하기 위해 이를 이용하는 방법
Porchia et al. Active immunization combined with cisplatin confers enhanced therapeutic protection and prevents relapses of HPV-induced tumors at different anatomical sites
US20230132140A1 (en) Method of treating cancer
KR20210052924A (ko) 작은 지질 나노 입자 및 이를 포함하는 암 백신
HK40106688A (en) Combination therapy against cancer
JP2021504336A (ja) 抗体依存性細胞媒介性細胞傷害（ａｄｃｃ）の強化